We believe people living with Alpha-Gal Syndrome deserve better. This nationwide research initiative is collecting patient experiences to better understand diagnosis, treatment outcomes, barriers to care, and what the future of Alpha-Gal healthcare should look like.
Anonymous · Voluntary · Estimated 10–15 minutes depending on your experience
Alpha-Gal Syndrome now affects an estimated 450,000 or more Americans — a number growing rapidly as lone star tick populations expand into new regions. Cases have increased more than 5,000% over the past decade, and the condition is now being identified in states where it was previously unknown.
Despite growing awareness, many patients continue to experience lengthy diagnostic delays, limited access to knowledgeable providers, and few coordinated treatment pathways. The result is a fragmented system where patients often navigate their condition largely alone — relying on online communities rather than clinical guidance.
Rezonate is conducting independent research into the Alpha-Gal patient experience. We are not currently a clinic or a pharmaceutical company, and are not affiliated with any treatment provider.
We are gathering comprehensive data on patient diagnosis journeys, treatment outcomes, access barriers, and unmet needs. This research will help us understand what better care looks like.
If you are living with Alpha-Gal Syndrome, your experience is exactly what this research needs.
Select the survey that matches your situation. Both are anonymous and take approximately 10–15 minutes to complete.
For patients who have undergone Soliman Auricular Allergy Treatment. Covers your treatment experience, outcomes, side effects, and long-term results.
Start this survey →For patients living with Alpha-Gal Syndrome who have not yet received SAAT treatment. Covers your diagnosis journey, access barriers, and what you need.
Start this survey →We are committed to protecting your privacy. We do not collect your name or any identifying information unless you voluntarily provide it at the end of the survey to opt into future follow-up.
Our goal is to share what we find. It is our intention to share aggregate findings from this study openly with the Alpha-Gal patient community.
Participation is entirely voluntary. You may stop at any time. There is no obligation and no consequence for not completing the survey.
We welcome questions, feedback, and direct outreach from patients, practitioners, and researchers.
research@rezonatemed.com